2020 Circulating free DNA (cfDNA) testing in lung cancer (pilot)

Scheme description
Circulating free DNA(cfDNA) testing for EGFR variant in plasma for lung cancer . Details to be confirmed including cost of participation.
Disorders/Gene target(s)
Lung Cancer
EGFR
Clinical cases
TBC
Testing/analysis
circulating tumour DNA
variant hotspots
Sample type
Plasma
Techniques
Any molecular testing methods.
Assessment
Submit a clinical report to include:
• Genotyping of results
• Interpretation of the result
• Clerical accuracy
Eligibility
Any laboratory worldwide
Languages
English ONLY
ISO17043 Accredited EQA
No
EQA timeline
Sample dispatchTBC
Testing periodTBC
Assessment resultsTBC
Final Summary reportTBC
Other information
Collaboration with IQNPath (ESP, AIOM, EMQN and Gen&Tiss)
Further details of this EQA will be updated when they are available.
The cost associated with participation in this EQA will be made available later.
Fee
£0.00
GenQA code
2020CFDNAL
« Return to EQA scheme list
Go to top